Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Harbor vs SynergenX Health

Harbor
Graded #86

Higher grade

vs+13.600000000000001
SynergenX Health
Graded #374

Lower grade

The verdict

Harbor takes it — 72/100 to 58.4/100.

Harbor grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Harbor is a physician-led telehealth platform offering compounded semaglutide (from $99/mo) and compounded tirzepatide (from $149/mo) — among the lowest headline prices in the market.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHarbor +28
74
46
Dose & formulationHarbor +12
64
52
Clinical oversightHarbor +23
89
66
Labs & monitoringSynergenX Health +23
63
86
FulfillmentHarbor +26
81
55
Contract termsEven
47
47
Harbor · left barSynergenX Health · right bar

The numbers

MetricHarborSynergenX Health
WeighScore72/10058.4/100
GradeCC
Scorecard rank#86#374
Semaglutide$99/mo (starting dose, compounded)$150/mo (starting dose, plus a separate fee, compounded)
Tirzepatide$149/mo (starting dose, compounded)Not disclosed
CoverageCoverage not published10 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Harbor

Graded #86 · C

Strengths

  • Compounded semaglutide from $99/mo and tirzepatide from $149/mo — among the lowest headline prices in the market
  • LegitScript certified with 4.7-star rating, 94.6% success rate, and 10,000+ verified members
  • 24/7 physician access with ongoing consultations, dosage adjustments, and free discreet shipping
  • 12-Month Money Back Guarantee if you don't reach your weight-loss goal
  • HSA/FSA eligible; no hidden fees, no insurance billed

Where it loses points

  • Compounded medications are not FDA-approved; compounding pharmacy names not publicly disclosed
  • Dietitian support offered only post-program (maintenance phase), not during active treatment
  • State-specific consultation types vary; nationwide availability unconfirmed for all states
  • No labs disclosed; patient portal is a third-party platform (mdintegrations), not native
  • Newer brand; success rate and member counts are on-site claims, not third-party verified
SynergenX Health

Graded #374 · C

Strengths

  • Compounded semaglutide from $150/mo including medication and refrigerated home shipping — no hidden fees stated on site
  • Backed by 64-clinic chain operating across 10 states with medical providers for in-person or telehealth care
  • Telehealth consultations from home; $100 initial visit, $40 follow-up every 1–3 months
  • Nutrition counseling and lifestyle planning included as part of personalized treatment program
  • Free weight-loss consultation option available before committing to paid evaluation

Where it loses points

  • Telehealth GLP-1 program currently Texas-only; rolling out more states but no timeline published
  • Tirzepatide not confirmed for online program; only compounded semaglutide explicitly listed
  • Labs not included or mentioned; no baseline bloodwork protocol disclosed on website
  • Dose-escalation pricing not published; $150/mo is entry dose only, higher doses may cost more
  • No LegitScript, named medical director, or publicly disclosed compounding pharmacy partner found

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard